Examination of Recent DDMAC Warning Letters: What You Can Learn From Other Companies' Mistakes
Product Details
Flash cards. Online marketing. DTC TV ads. Even YouTube videos and pharmacy printouts.
Lately, it seems like no promotion is safe from DDMAC warning letters ... including yours.
And with DDMAC ranks recently bolstered by a dozen new reviewers, scrutiny under the Obama administration can only heat up.
So after you’ve invested a small fortune in high-quality marketing, how can you make sure your ads and promotions aren’t the next DDMAC victims?
Alert: The GAO just released a statement indicating that the FDA must “more systemically review the claims made in drug advertising and promotional material, and ensure that drug sponsors accurately report clinical trial results.”
Find out how to keep your advertisements and promotions safe from an FDA violation by learning from actual, recent warning letters. Order now and you’ll:
- Discover the red flags guaranteed to result in DDMAC enforcement — critical for all your current and future advertising and promotional materials
- See side-by-side comparisons of recent real-life warning letters along with the specific mistakes in the marketing materials that generated them
- Stay one step ahead — examine the most recent DDMAC enforcement trends
- Understand why you must coordinate marketing and regulatory affairs departments
- Gain an inside-the-beltway perspective on DDMAC under the new Obama administration (and what it could mean for you)
Remember, if DDMAC decides you’ve made an exaggerated claim ... or failed to mention a product’s specific risks ... or even hinted at an “off-label” indication, you can bet they’ll come knocking on your door. Why take the chance?
Find out how to safeguard your marketing materials — and the substantial investment required to create them — from a DDMAC strike. Don’t let this opportunity pass you by!